Sarcoma is rare kind of cancer that occurs in the connective tissues of the body. Normal connective tissue include blood vessels, fat, nerves, muscles, deep skin tissues, bones, and cartilage. There are more than 50 types of sarcomas. However, they are mainly classified into two types: soft tissue sarcomas and bone sarcomas. They are further divided based on presumed cell of origin found in the tumor. Soft tissue sarcoma is the most common type of sarcoma, accounting for more than 80% of all sarcoma cases. Sarcoma affects all age groups but is more common in children. It is estimated that about 15% of cancer diagnosis in children are sarcomas. Rise in the incidence and prevalence of sarcoma, strong clinical pipeline of sarcoma drugs, rise in government initiatives toward orphan drug development, and increase in research and development expenditure are likely to fuel the growth of the global sarcoma market during forecast period. However, disappointing results of promising pipeline molecules, high cost of treatment and side effect associated with it, and stringent government regulations are estimated to hamper the growth of the global sarcoma market in in the coming years. 

The global sarcoma market can be segmented based on type, treatment, and geography. Based on type, the sarcoma market can be segmented into soft tissue sarcoma and bone sarcoma. The soft tissue sarcoma segment is expected to hold a significant share of the market during forecast period, owing to high incidence and prevalence rate of soft tissue sarcoma. In terms of treatment, the global sarcoma market can be categorized into chemotherapy, surgery, radiation therapy, and others (stem cell therapy). The chemotherapy segment generally includes a combination of various anti-neoplastic drugs. The commonly used chemotherapeutics agents are dactinomycin, etoposide, irinotecan, doxorubicin, carboplatin, ifosfamide, vincristine, among others. The chemotherapy segment expected to account for a significant share of the market during forecast period due to high cost of chemotherapy and it preference as the first line therapy for the treatment of sarcoma. Rise in the incidence and prevalence of sarcoma, increase in demand for targeted therapy and personalized therapy, and significant pipeline molecules (such as afatinib and temsirolimus) are likely to propel the market in the near future. Furthermore, development of new products with improved efficacy as a part of growth strategies adopted by a number of players and strategic deals, mergers, and acquisitions in the sarcoma market are estimated to drive the market in the next few years. 

In terms of geography, the global sarcoma market can be segmented into North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. North America is anticipated to be a dominant region of the market, followed by Europe. The high incidence of sarcoma (around 15,000 new cases are diagnosed each year in the U.S.), growing awareness among people, increase in research and development expenditure, strong clinical pipeline, and well-established health care infrastructure contribute to the growth of the sarcoma market in North America. The market in Asia Pacific is anticipated to expand at a high CAGR during the forecast period. The market is likely to be driven by India and China, owing to a significant patient base, increased government initiatives, and developing health care infrastructure. The market in Latin America and Middle East & Africa is anticipated to expand during the forecast period, owing to an increase in investments from market players in these regions and increase in prevalence of sarcoma. 

The leading players in the global sarcoma market include Eli Lilly and Company, CytRx, Boehringer Ingelheim, Ovation Pharmaceuticals, Inc., Pfizer, Tracon Pharma, Karyopharm Therapeutics, Blueprint Medicines, Advenchen Laboratories, Oasmia Pharmaceutical, and Arog Pharmaceuticals.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

The study is a source of reliable data on:

  • Market segments and sub-segments
  • Market trends and dynamics
  • Supply and demand
  • Market size
  • Current trends/opportunities/challenges
  • Competitive landscape
  • Technological breakthroughs
  • Value chain and stakeholder analysis

The regional analysis covers:

  • North America (U.S. and Canada)
  • Latin America (Mexico, Brazil, Peru, Chile, and others)
  • Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)
  • Eastern Europe (Poland and Russia)
  • Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)
  • Middle East and Africa (GCC, Southern Africa, and North Africa)

The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.

A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.

Highlights of the report:

  • A complete backdrop analysis, which includes an assessment of the parent market
  • Important changes in market dynamics
  • Market segmentation up to the second or third level
  • Historical, current, and projected size of the market from the standpoint of both value and volume
  • Reporting and evaluation of recent industry developments
  • Market shares and strategies of key players
  • Emerging niche segments and regional markets
  • An objective assessment of the trajectory of the market
  • Recommendations to companies for strengthening their foothold in the market   

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.       

.